$185MSeries A, 5 November 2025
Funds late-stage development of BHB-1893 with trials planned from 2026.
- Amount
- $185M
- Stage
- Series A
- Announced
- 5 November 2025
- Lead
- Andreessen Horowitz
- Other investors
- Forbion, OrbiMed, Enavate Sciences, Frazier Life Sciences
- Use of funds
- Funds late-stage development of BHB-1893 with trials planned from 2026.
- Checked
- Amount and date matched across 2 press sources
- Sources
- Braveheart Bio raises $185M vcaonline.com
Braveheart Bio raises $185M goodwinlaw.com